Quadrant Capital Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.17M | Buy |
20,772
+1,436
| +7% | +$83.7K | 0.04% | 493 |
|
|
2025
Q4 | $1.15M | Buy |
19,336
+14,918
| +338% | +$812K | 0.03% | 477 |
|
|
2025
Q3 | $239K | Sell |
4,418
-7,740
| -64% | -$443K | 0.01% | 1214 |
|
|
2025
Q2 | $668K | Buy |
12,158
+1,148
| +10% | +$67.6K | 0.02% | 695 |
|
|
2025
Q1 | $778K | Buy |
11,010
+9,234
| +520% | +$621K | 0.03% | 490 |
|
|
2024
Q4 | $117K | Buy |
1,776
+658
| +59% | +$44.1K | 0.01% | 976 |
|
|
2024
Q3 | $78.6K | Buy |
1,118
+687
| +159% | +$57.4K | 0.01% | 1217 |
|
|
2024
Q2 | $35.5K | Buy |
431
+266
| +161% | +$22.1K | ﹤0.01% | 1579 |
|
|
2024
Q1 | $14.4K | Buy |
165
+14
| +9% | +$1.25K | ﹤0.01% | 1979 |
|
|
2023
Q4 | $14.6K | Buy |
151
+19
| +14% | +$1.68K | ﹤0.01% | 1929 |
|
|
2023
Q3 | $11.7K | Sell |
132
-327
| -71% | -$29.1K | ﹤0.01% | 1933 |
|
|
2023
Q2 | $39.8K | Sell |
459
-62
| -12% | -$5.83K | ﹤0.01% | 1374 |
|
|
2023
Q1 | $50.7K | Buy |
521
+290
| +126% | +$30.1K | 0.01% | 1237 |
|
|
2022
Q4 | $23.9K | Sell |
231
-17
| -7% | -$1.6K | ﹤0.01% | 1578 |
|
|
2022
Q3 | $21K | Sell |
248
-107
| -30% | -$9.53K | ﹤0.01% | 1501 |
|
|
2022
Q2 | $29K | Buy |
355
+232
| +189% | +$18.5K | ﹤0.01% | 1113 |
|
|
2022
Q1 | $9K | Sell |
123
-120
| -49% | -$10K | ﹤0.01% | 1680 |
|
|
2021
Q4 | $21K | Buy |
243
+8
| +3% | +$660 | ﹤0.01% | 1279 |
|
|
2021
Q3 | $18K | Sell |
235
-10
| -4% | -$789 | ﹤0.01% | 1281 |
|
|
2021
Q2 | $20K | Sell |
245
-104
| -30% | -$8.24K | ﹤0.01% | 1194 |
|
|
2021
Q1 | $26K | Buy |
349
+115
| +49% | +$9.39K | ﹤0.01% | 1067 |
|
|
2020
Q4 | $21K | Sell |
234
-13
| -5% | -$1.03K | ﹤0.01% | 1074 |
|
|
2020
Q3 | $19K | Sell |
247
-521
| -68% | -$52.7K | ﹤0.01% | 967 |
|
|
2020
Q2 | $95K | Sell |
768
-854
| -53% | -$84.9K | 0.02% | 471 |
|
|
2020
Q1 | $137K | Buy |
1,622
+1,111
| +217% | +$95.7K | 0.02% | 474 |
|
|
2019
Q4 | $41K | Sell |
511
-432
| -46% | -$32.6K | ﹤0.01% | 1431 |
|
|
2019
Q3 | $62K | Sell |
943
-940
| -50% | -$72.4K | 0.01% | 1134 |
|
|
2019
Q2 | $156K | Buy |
1,883
+643
| +52% | +$55K | 0.02% | 671 |
|
|
2019
Q1 | $105K | Buy |
1,240
+880
| +244% | +$81.6K | 0.02% | 780 |
|
|
2018
Q4 | $26K | Sell |
360
-82
| -19% | -$7.8K | 0.01% | 1097 |
|
|
2018
Q3 | $38K | Hold |
442
| – | – | 0.01% | 742 |
|
|
2018
Q2 | $36K | Buy |
442
+113
| +34% | +$9.9K | 0.01% | 761 |
|
|
2018
Q1 | $21K | Sell |
329
-30
| -8% | -$2.58K | 0.01% | 933 |
|
|
2017
Q4 | $27K | Sell |
359
-95
| -21% | -$8.26K | 0.01% | 818 |
|
|
2017
Q3 | $36K | Buy |
454
+52
| +13% | +$4.59K | 0.01% | 701 |
|
|
2017
Q2 | $31K | Buy |
402
+81
| +25% | +$7.37K | 0.01% | 708 |
|
|
2017
Q1 | $23K | Buy |
321
+48
| +18% | +$4.27K | 0.01% | 784 |
|
|
2016
Q4 | $17K | Sell |
273
-59
| -18% | -$5.07K | 0.01% | 811 |
|
|
2016
Q3 | $26K | Hold |
332
| – | – | 0.02% | 655 |
|
|
2016
Q2 | $22K | Buy |
332
+196
| +144% | +$16.7K | 0.02% | 662 |
|
|
2016
Q1 | $9K | Buy |
136
+31
| +30% | +$2.52K | 0.01% | 991 |
|
|
2015
Q4 | $8K | Buy |
105
+27
| +35% | +$2.82K | 0.01% | 866 |
|
|
2015
Q3 | $8K | Buy |
+78
| New | +$10.4K | 0.01% | 719 |
|
Other funds holding BMRN
VCM
VPM
Quadrant Capital Group's BMRN Position: Q1 2026 in Review
Quadrant Capital Group increased its BioMarin Pharmaceuticals (BMRN) stake by 7.4% in Q1 2026, buying an estimated $83.7K and bringing the position to 20,772 shares worth $1.17M. The position accounts for 0.04% of the portfolio, ranked #493.
Quadrant Capital Group first reported a position in BMRN in Q3 2015 and has held it in 43 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Quadrant Capital Group held 20,772 shares of BioMarin Pharmaceuticals worth $1.17M as of Q1 2026.
- Quadrant Capital Group bought 1,436 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $83.7K.
- BioMarin Pharmaceuticals made up 0.04% of Quadrant Capital Group's portfolio in Q1 2026, its #493 holding.
- Quadrant Capital Group first reported a position in BioMarin Pharmaceuticals in Q3 2015 and has held it in 43 quarters since.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.